Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises KEYTO Group in connection with the acquisition of Enspecta
Mandate

Vinge advises KEYTO Group in connection with the acquisition of Enspecta

July 01, 2025 M&A IT, Telecommunications and Outsourcing Data protection and processing of personal data Insurance Law Employment and Benefits Commercial Agreements Intellectual Property

KEYTO Group continues its growth journey by strengthening its offering in Sweden as Enspecta joins the group. This strategic addition marks KEYTO’s entry into a new service vertical focused on home inspection, assessment and optimisation - and reinforces the ambition of a leading, tech-enabled one-stop destination for home-related services. 

Vinge's team mainly consisted of Jonas Bergström, Gustav Wahlberg and Ian Linde (M&A), Carla Håkansson and Gabriel Pålsson (Commercial Agreements), William Karo Persson and Ida Pettersson (Employment), Melinda Oldenburg (IP), Nicklas Thorgenzon and Sara Link (IT and GDPR), Olivia Carlsten and Josef Jatta Kölin (Insurance) and Caroline Löv (Transaction Support Coordinator). 

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025